Compare Danaher Corporation (DHR) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Nucor Corporation — how do they compare? Danaher Corporation trades at $219.93 (market cap $152.87B), while Nucor Corporation trades at $250.53 (market cap $55.84B). The key difference: Danaher Corporation is far larger — about 2.7× Nucor Corporation's market cap, and Nucor Corporation pays the higher dividend (0.91%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Nucor Corporation for 78 Days on average.
| DHR | NUE | |
|---|---|---|
Market Cap | $152.87B | $55.84B |
Volume | 5,228,698 | 848,835 |
Sector | Health | Basic Materials |
52-Week High | $242.05 | $274.74 |
52-Week Low | $161.91 | $131.78 |
Typical Hold Time | 69 Days | 78 Days |
Enterprise Value | $175.08B | $60.25B |
Dividend Yield | 0.74% | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
Nucor (NUE) trades at $246.44, down 1.84% on the day, with a neutral technical signal and mixed earnings history including a Q2 2026 beat. Revenue and net income have shown volatility, with 2025 revenue at $32.49B and net income at $1.74B, while analyst consensus is a 'Buy' with a $266.88 price target. Recent news highlights steel sector dynamics and Nucor's Q3 2026 earnings guidance.
The outlook for NUE is cautiously optimistic, supported by analyst bullishness and projected earnings growth, but risks include competitive pressures from new steel capacity and cyclical demand fluctuations. Investment opportunity lies in its solid fundamentals and dividend history, though investors should weigh margin pressures and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
